Kedrion Biopharma

Sustainability Report and Carbon Intensity Rankings

Is Kedrion Biopharma doing their part?

Their DitchCarbon score is 48

Kedrion Biopharma has a DitchCarbon Score of 48 out of 100, indicating a moderate level of sustainability in their operations. This score suggests that the company’s carbon intensity is relatively high, implying there is significant room for improvement in reducing emissions. Efforts to lower carbon intensity would enhance Kedrion Biopharma’s sustainability profile and contribute to better environmental performance.

This was calculated based on 30+ company specific emissions data points, the higher the score, the better. Check out our methodology.

Industry emissions intensity

Very low

Low

Medium

High

Very high

Kedrion Biopharma is part of the research and development sector, which has a carbon intensity ranking of very low. Some industries are more damaging than others, this ranking gives you an indication of how carbon intensive the industry is which this company operates in.

Location emissions intensity

Very low

Low

Medium

High

Very high

Kedrion Biopharma, located in Italy, benefits from the country’s low carbon intensity rating. This favorable environmental context supports the company’s sustainability efforts by reducing its carbon footprint.

Unlock 30+ emissions data points on Kedrion Biopharma

Get the emissions intelligence you need, no surveys required.

– Historical Scope 1, 2 and 3 emissions

– Coverage of all industries, product level data

– Emissions forecasting, assurances

Unlock 30+ emissions data points on Kedrion Biopharma

Get the emissions intelligence you need, no surveys required.

– Historical Scope 1, 2 and 3 emissions

– Coverage of all industries, product level data

– Emissions forecasting, assurances

3.36%

...this company is doing 3.36% worse in emissions than the industry average.

Kedrion Biopharma, founded in 2001 and headquartered in Italy, operates in the biopharmaceutical industry, specializing in the research, development, and production of plasma-derived therapies. The company plays a significant role in the global healthcare sector, providing treatments for rare and chronic conditions to patients in approximately 100 countries. With facilities in Italy, Hungary, and the United States, and plasma collection centers across multiple countries, Kedrion Biopharma is committed to expanding access to life-enhancing plasma therapies and fostering a diverse professional workforce.

emission intelligence's platform recommendations for Kedrion Biopharma

Kedrion Biopharma should enhance their machinery and equipment to be cleaner and more efficient, which could potentially reduce their emissions by 15%.

Bad news, Kedrion Biopharma hasn't committed to SBTi goals yet.

Kedrion Biopharma has not yet established specific commitments with the Science Based Targets initiative (SBTi). This means the company is still in the process of defining clear, science-based emissions reduction targets to align with global efforts to limit warming.
Not participating

Claim this profile

Are you associate with this company?
Help us improve our data and claim this profile.

Our methodology

Read about our emission calculation methodologies, and what the DitchCarbon Score means.

Looking for a specific company?

Search our company directory or contact us for custom data requests.